For years, the big pharmaceutical companies have been chasing the holy grail of diabetes therapies – non-injectable insulin. A range of such products are set to explode on to the market in the next few years, ensuring a bitter grapple for market share.
The company is launching in Ecuador first due to their more relaxed drug trial requirements and they expect to use the revenue from the sale of the drug in South America to fund more expensive phase III trials for the US and Europe.
via: In Pharma Technologist